Mydecine Innovations Group Inc. (MYCOF)
Chart Events
Performance Outlook
| Previous Close | 0.2770 |
| Open | 0.3000 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.2700 - 0.3000 |
| 52 Week Range | 0.1990 - 2.2000 |
| Volume | 689,314 |
| Avg. Volume | 657,203 |
| Market Cap | 66.522M |
| Beta (5Y Monthly) | 4.50 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1510 |
| Earnings Date | May 18, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.00 |
Fair Value
Related Research
- MYDECINE INNOVATIONS GROUP INCAnalyst Report: Lions Gate Entertainment Corp.Lionsgate produces and distributes motion pictures and television shows globally through theatrical, television, home video, and digital platforms. It acquired Summit Entertainment, another small studio, in January 2012 and the Starz premium cable channel in December 2016. A primary focus for the company is the young adult audience. It has two mega-grossing franchises in 'The Hunger Games' and 'The Twilight Saga,' as well as a number of lower-profile genre-oriented titles targeted at the horror, urban, and Hispanic markets. The company generated 18% of its FY18 revenue outside the U.S. With the Starz merger, Lionsgate created two new share classes to replace its old share classes. The new Lionsgate Series A voting shares are denominated LGF.A by the company, LGF/A by Bloomberg, and LGF-A by Yahoo Finance. The Series B nonvoting shares are likewise denominated LGF.B by the company, LGF/B by Bloomberg, and LGF-B by Yahoo Finance. There are 83 million Series A shares outstanding, and the LGF/A ticker retains the historical and volume trading data. There are 137.5 million Series B shares outstanding. Investors should note that Argus covers the ticker LGF/A, and therefore the market capitalization on the Argus website reflects only LGF/A and not the combined LGF/A and LGF/B shares.RatingFair ValueEconomic Moatlast yearArgus Research
- CNW Group
KCSA Psychedelics Virtual Investor Conference Agenda Announced for October 13th & 14th
Virtual Investor Conferences in partnership with KCSA Strategic Communications today announced the agenda for the upcoming KCSA Psychedelics Virtual Investor Conference. Individual investors, institutional investors, advisors, and analysts are invited to attend the two-day program beginning Wednesday, October 13, 2021, at 9:45 a.m. ET.
- PR Newswire
Mydecine to Present at the KCSA Psychedelics Virtual Investor Conference on October 14th
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company'), a biopharmaceutical company focused on the treatment of mental health disorders and addiction, today announced that Josh Bartch, CEO of Mydecine, will participate in the KCSA Psychedelics Investor Conference to be held at VirtualInvestorConferences.com on October 13-14, 2021.
- GlobeNewswire
Mydecine To Supply Lead Drug Candidate, MYCO-001, for Multi-Site NIDA Grant-Funded Smoking Cessation Study Lead by Dr. Matthew Johnson
Research to take place at Johns Hopkins, New York University and University of Alabama BirminghamDENVER, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), a biopharmaceutical company focused on the treatment of mental health disorders and addiction, today announced that it plans to supply its lead drug candidate, MYCO-001, for a multi-site smoking cessation study being conducted at Johns Hopkins University (“JHU”), Ne
